eFFECTOR Therapeutics News

8-K: Current report

May 20 20:40

424B3: Prospectus

May 18 05:10

8-K: Current report

May 18 05:04

4: Statement of changes in beneficial ownership of securities-Officer Byrnes Michael

May 18 04:03

4: Statement of changes in beneficial ownership of securities-Officer WORLAND STEPHEN T

May 18 04:03

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Carlyle Group Inc.(4.1%),Carlyle Holdings I GP Inc.(4.1%), etc.

May 14 04:11

424B5: Prospectus

May 10 05:16

424B3: Prospectus

May 10 04:55

8-K/A: Current report (Amendment)

May 10 04:38

8-K: eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 10 04:15

8-K: Current report

May 10 04:14

10-Q: Quarterly report

May 10 04:10

ARS: Annual Report to Security Holders

Apr 26 18:18

DEFA14A: Others

Apr 26 18:13

DEF 14A: Definitive information statements

Apr 26 18:13

PRE 14A: Preliminary proxy statements relating to merger or acquisition

Apr 16 20:05

eFFECTOR Therapeutics | 424B3: Prospectus

Apr 4 20:45

eFFECTOR Therapeutics | 8-K: Current report

Apr 4 20:40

eFFECTOR Therapeutics | 424B5: Prospectus

Apr 4 20:20

eFFECTOR Therapeutics | EFFECT: Others

Apr 3 18:07